860805-86-3Relevant articles and documents
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl) propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist
Dwyer, Michael P.,Yu, Younong,Chao, Jianping,Aki, Cynthia,Chao, Jianhua,Biju, Purakkattle,Girijavallabhan, Viyyoor,Rindgen, Diane,Bond, Richard,Mayer-Ezel, Rosemary,Jakway, James,Hipkin, R. William,Fossetta, James,Gonsiorek, Waldemar,Bian, Hong,Fan, Xuedong,Terminelli, Carol,Fine, Jay,Lundell, Daniel,Merritt, J. Robert,Rokosz, Laura L.,Kaiser, Bernd,Li, Ge,Wang, Wei,Stauffer, Tara,Ozgur, Lynne,Baldwin, John,Taveras, Arthur G.
, p. 7603 - 7606 (2006)
Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity. Compound 4 displayed good oral bioavailability in rat and may be a potential therapeutic agent for the treatment of various inflammatory diseases.
THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS
-
Page 259, (2008/06/13)
Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).
